Barry R. Davis, MD, PhD; Jeffrey A. Cutler, MD; Curt D. Furberg, MD, PhD; Jackson T. Wright, MD, PhD; Michael A. Farber, MD; James V. Felicetta, MD; John D. Stokes, MD; ALLHAT Collaborative Research Group*
Grant Support: By contract NO-HC-35130 from the National Heart, Lung, and Blood Institute. Study medications were supplied by Pfizer, Inc. (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), and Bristol-Myers Squibb (pravastatin); Pfizer, Inc., provided financial support to the National Heart, Lung, and Blood Institute.
Potential Financial Conflicts of Interest:Consultancies: B.R. Davis, J.T. Wright Jr., J.V. Felicetta; Honoraria: C.D. Furberg, J.T. Wright Jr., J.V. Felicetta; Stock Ownership: M.A. Farber; Grants Received: C.D. Furberg, J.T. Wright Jr., J.V. Felicetta.
Requests for Single Reprints: Barry R. Davis, MD, PhD, the University of Texas School of Public Health, 1200 Herman Pressler Street, Houston, TX 77030; e-mail, firstname.lastname@example.org.
Current Author Addresses: Dr. Davis: The University of Texas School of Public Health, 1200 Herman Pressler Street, Houston, TX 77030.
Dr. Cutler: The National, Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Bethesda, MD 20892.
Dr. Furberg: Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157.
Dr. Wright: Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106.
Dr. Farber: Pitman Internal Medicine Associates, 410 North Broadway, Pitman, NJ.
Dr. Felicetta: Carl T. Hayden Veterans Affairs Medical Center, 650 East Indian School Road, Phoenix, AZ 85012.
Dr. Stokes: 2323 Curlew Road, Palm Harbor, FL 34683.
Author Contributions: Conception and design: B.R. Davis, J.A. Cutler, C.D. Furberg, J.T. Wright.
Analysis and interpretation of the data: B.R. Davis, J.A. Cutler, C.D. Furberg, J.T. Wright.
Drafting of the article: B.R. Davis, J.A. Cutler, J.T. Wright, M.A. Farber.
Critical revision of the article for important intellectual content: B.R. Davis, J.A. Cutler, C.D. Furberg, J.T. Wright, M.A. Farber, J.V. Felicetta, J.D. Stokes.
Final approval of the article: B.R. Davis, J.A. Cutler, C.D. Furberg, J.T. Wright, J.V. Felicetta.
Provision of study materials or patients: B.R. Davis, M.A. Farber, J.D. Stokes.
Statistical expertise: B.R. Davis.
Obtaining of funding: B.R. Davis, J.A. Cutler.
Administrative, technical, or logistic support: B.R. Davis, J.A. Cutler, C.D. Furberg.
Collection and assembly of data: B.R. Davis, J.V. Felicetta, J.D. Stokes.
Davis BR, Cutler JA, Furberg CD, Wright JT, Farber MA, Felicetta JV, et al. Relationship of Antihypertensive Treatment Regimens and Change in Blood Pressure to Risk for Heart Failure in Hypertensive Patients Randomly Assigned to Doxazosin or Chlorthalidone: Further Analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Ann Intern Med. 2002;137:313-320. doi: 10.7326/0003-4819-137-5_Part_1-200209030-00006
Download citation file:
Published: Ann Intern Med. 2002;137(5_Part_1):313-320.
The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT), a randomized, double-blind, multicenter clinical trial including 42 418 participants at 623 clinical sites, is designed to determine whether treatment begun with a calcium-channel blocker (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), or an α-adrenergic blocker (doxazosin) compared to treatment with a diuretic (chlorthalidone) reduces the incidence of fatal coronary heart disease or nonfatal myocardial infarction in high-risk patients with hypertension (1). Secondary end points are all-cause mortality, stroke, and other cardiovascular events. A lipid-lowering trial in a subset of 10 356 participants is designed to determine whether decreasing cholesterol levels with a hydroxymethyl glutamyl coenzyme A reductase inhibitor (pravastatin) compared with usual care reduces all-cause mortality in older, moderately hypercholesterolemic patients.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Nephrology, Hypertension, Heart Failure, Coronary Risk Factors.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only